Stung by a court decision late last year that invalidated its patents for its second best-selling drug, Allergan said it will eliminate 1400 jobs—1000 now-filled and 400 open positions—in a restructuring designed to cut costs. Employees to be laid off, Allergan said in a regulatory filing yesterday, are in commercial positions that “primarily focus on products and categories subject to …

Stung by a court decision late last year that invalidated its patents for its second best-selling drug, Allergan said it will eliminate 1400 jobs—1000 now-filled and 400 open positions—in a restructuring designed to cut costs. Employees to be laid off, Allergan said in a regulatory filing yesterday, are in commercial positions that “primarily focus on products and categories subject to …